Papula-Nevinpat official IP partner at Junction 2016, Europe’s leading hackathon

18.11.2016

Papula-Nevinpat is proud to be part of this year’s Junction as the official IPR partner. Junction, Europe’s biggest hackathon takes place 25 – 27 November 2016 at Wanha Satama in Katajanokka, Helsinki, Finland.

“Junction 2016 is about innovation and entrepreneurship: 1 200 developers, designers and entrepreneurs from across the world gather together to work and solve challenges that partner companies provide. As the goal is to establish new innovative actual projects, it is important to keep also intellectual property rights in mind”, says Teemu Lang, CDO, Papula-Nevinpat. “Papula-Nevinpat has a long and wide experience in working with startups. We want to help them understand how extremely important it is to take care of IP rights from the outset of a new business.”

Partners of Junction include for example UPM, Tieto and Nokia from Finland and GE, Twitter and Skype. This year the emphasis is on virtual reality, other focus areas include Internet of Things and healthtech.

Junction is Europe’s leading hackathon and a converging point for developers, designers, and entrepreneurs from across the world. Junction is a non-profit event organized by Aalto Entrepreneurship Society (Aaltoes).

Read more about Junction.logo_main_blackJunction

 

News

Riikka Palmos and Jussi Mikkola of Papula-Nevinpat have secured their positions in the top tiers by WTR 1000 for 2025

Papula-Nevinpat’s trademark practice has once again been recognized in the top tier of the 2025 edition of the World Trademark Review 1000.

Papula-Nevinpat is thrilled to continue its partnership as the IPR partner for ESA BIC Finland

Papula-Nevinpat is pleased to continue as the ESA BIC Finland program's intellectual property rights (IPR) partner.

Papula-Nevinpat in PTMG’s newsletter: The Evolving Landscape in Ukraine and Russia – Challenges and Strategies for Rights Holders

Riikka Palmos, a European Trademark Attorney, has authored an article discussing key developments in Ukraine and Russia. You can read the article in the latest PTMG (Pharmaceutical Trade Marks Group) newsletter.